Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Pediatric lung transplantation: The years 1985 to 1992 and the clinical trial of FK 506

Armitage, JM and Fricker, FJ and Kurland, G and Hardesty, RL and Michaels, M and Morita, S and Starzl, TE and Yousem, SA and Jaffe, R and Griffith, BP and Bolman, RM and Shennib, H (1993) Pediatric lung transplantation: The years 1985 to 1992 and the clinical trial of FK 506. Journal of Thoracic and Cardiovascular Surgery, 105 (2). 337 - 346. ISSN 0022-5223

Accepted Version
Available under License : See the attached license file.

Download (3MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


The application of lung transplantation to the pediatric population was a natural extension of the success realized in our adult transplantation program, which began in 1982. Twenty pediatric patients (age range 3 to 18 years) have had heart-lung (n = 11), double lung (n = 8), and single lung (n = 1) transplantation procedures. The causes of end-stage lung disease were primary pulmonary hypertension (n = 7), congenital heart disease (n = 5), cystic fibrosis (n = 4), pulmonary arteriovenous malformation (n = 2), graft- versus-host disease (n = 1), and desquamative interstitial pneumonitis (n = 1). Four (20%) patients had thoracic surgical procedures before the transplantation operation. The survival was 80% at a mean follow-up of 2 years. Immunosuppressive drugs included cyclosporine (n = 9) or FK 506 (n = 11) based therapy with azathioprine and steroids. Children were followed up by means of spirometry, transbronchial biopsy, and primed lymphocyte testing of bronchoalveolar lavage fluid. The mean number of treated episodes of rejection was 1.4 at 30 days, 0.5 at 30 to 90 days, and 1.4 at more than 90 days, and the first treated rejection episode occurred on average 28 days after the operation. Obliterative bronchiolitis developed in four (25%) of 16 patients surviving more than 100 days. Results of pulmonary function tests have remained good in almost all recipients. The greatest infectious risk was that of cytomegalovirus: one death and one case of pneumonia. Posttransplantation lymphoproliferative disease was diagnosed in two (12.5%) patients; both recovered. The most common complications were hypertension (25%) and postoperative bleeding (15%). Early results indicate that lung transplantation is a most promising therapy for children with severe vascular and parenchymal lung disease.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Armitage, JM
Fricker, FJ
Kurland, G
Hardesty, RL
Michaels, M
Morita, S
Starzl, TEtes11@pitt.eduTES11
Yousem, SAyousem@pitt.eduYOUSEM
Jaffe, R
Griffith, BP
Bolman, RM
Shennib, H
Centers: Other Centers, Institutes, Offices, or Units > Thomas E. Starzl Transplantation Institute
Date: 1 January 1993
Date Type: Publication
Journal or Publication Title: Journal of Thoracic and Cardiovascular Surgery
Volume: 105
Number: 2
Page Range: 337 - 346
DOI or Unique Handle: 10.1016/s0022-5223(19)33820-6
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 0022-5223
Other ID: uls-drl:31735062113331, Starzl CV No. 1546
Date Deposited: 08 Apr 2010 17:26
Last Modified: 03 Jul 2020 14:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item